BioSpace News Archive

Increasing demand for precise diagnosis methods is one of the significant factors influencing the market growth.

The growing incidence of cancer and cardiac diseases coupled with advancement in technology is driving the optical coherence tomography market.

The increase in the prevalence of Parkinson’s and Alzheimer’s diseases and rising awareness regarding the transcranial magnetic stimulators are driving the market.

An emerging field explores how groups of molecules condense together inside cells, the way oil droplets assemble and separate from water in a vinaigrette.

On Demand Pharmaceuticals, Inc. (ODP), and Wavelength Pharmaceuticals ( Petah Tikva , Israel ) - a SEQENS company, are pleased to announce that the US-Israel Binational Industrial Research & Development (BIRD) Foundation grant.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, California.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.

NanoVibronix, Inc . , (NASDAQ: NAOV) (the “Company”), announced today that its annual meeting of shareholders (the “Annual Meeting”) will take place at 10 a.m. Eastern time on December 15, 2022.

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, announced the pricing of its upsized initial public offering of 10,900,000 shares of its common stock at a public offering price of $17.00 per share.

Rhythm Pharmaceuticals, Inc. announced the pricing of its public offering of 4,800,000 shares of its common stock at a public offering price of $26.00 per share.